Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
|Slideshows|January 10, 2022
US Flu Activity for the Week Ended 1/1/2022
Author(s)Grace Halsey
Click through top flu indicators tracked by the Centers for Disease Control and Prevention weekly US influenza surveillance report.
Advertisement
Currently the cumulative hospitalization rate is higher than that for the entire 2020-2021 flu season, although still lower than rates seen at this time during several seasons preceding
Here is a top-line look at other indicators being tracked for the week ended 1/1/2022.
Advertisement
Related to this article
A Vaccine Integrity Project review found influenza, COVID-19, and RSV immunizations continue to protect against severe illness, hospitalization, and death.
FDA approved Pfizer-BioNTech’s XFG-adapted COMIRNATY formula for adults 65 and older and high-risk people aged 5 to 64 years.
FDA approved bictegravir/lenacapavir for adults with suppressed HIV-1 and no known or suspected component resistance.
ACOG's new guideline covers hormone therapy timing, neurokinin receptor antagonists, SSRIs/SNRIs, and nonpharmacologic options for menopause symptoms.
Post hoc LUCENT-2 and VIVID-1 analyses show more mirikizumab-treated patients reached steroid-free composite remission in UC and Crohn disease at 1 year.
The FDA granted Breakthrough Device designation to Natera's cell-free DNA multi-cancer early detection assay. What it means for primary care.
Most adolescents with sporadic colorectal cancer present with stage III or IV disease, and few have a family history, per data presented at AAP 2026.
Advertisement
Advertisement
Trending on Patient Care Online
1
Who Should Get a CGM? Expanding the Primary Care Candidate Pool
2
FDA Grants Breakthrough Device Designation to Natera's Multi-Cancer Early Detection Blood Test
3
ACOG Issues Expanded Guideline on Managing Menopause-Related Vasomotor, Sleep, and Mood Symptoms
4
Mirikizumab Linked to Higher Rates of Corticosteroid-Free Composite Remission in UC and Crohn Disease
5